The Effect of Prescription Medications in Marijuana Users
Information source: Johns Hopkins University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Marijuana Abuse
Intervention: bupropion, diazepam, dronabinol, ramelteon (Investigational Drug) (Drug)
Phase: Phase 1/Phase 2
Status: Recruiting
Sponsored by: Johns Hopkins University Official(s) and/or principal investigator(s):
Ryan Vandrey, Ph.D., Principal Investigator, Affiliation: Johns Hopkins University
Overall contact:
Sarah Ilk, Phone: 410-550-0007
Summary
A subset of heavy marijuana users have trouble quitting marijuana use and the number of
those seeking treatment for problems related to marijuana is increasing. The purpose of
this research study is to investigate whether certain medications can reduce withdrawal
effects associated with stopping marijuana use, if they can reduce the rewarding effects of
smoked marijuana, and whether there are any cognitive performance deficits associated with
the medications that produce such effects.
Clinical Details
Official title: The Effect of Prescription Medications in Marijuana Users
Study design: Basic Science, Non-Randomized, Double Blind (Subject, Outcomes Assessor), Crossover Assignment, Safety/Efficacy Study
Primary outcome: marijuana withdrawalsubjective effects of smoked marijuana
Secondary outcome: cognitive performance
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- current use of marijuana
- able to give informed consent
Exclusion Criteria:
- dependence on drug other than marijuana
- pregnant, breast feeding, or planning to become pregnant within the next 3 months
- currently seeking treatment for cannabis-related problems or otherwise trying to
reduce use
- use of cannabis under the guidance of a physician for a medical disorder
- unstable or uncontrolled cardiovascular disease (e. g., hypertension, angina)
- allergy to study medication
Locations and Contacts
Sarah Ilk, Phone: 410-550-0007
Behavioral Pharmacology Research Unit, Baltimore, Maryland 21224, United States; Recruiting
Sarah Ilk, Phone: 410-550-0007
Ryan Vandrey, Ph.D., Principal Investigator
Additional Information
Starting date: April 2009
Ending date: May 2011
Last updated: May 4, 2009
|
